Detalhe da pesquisa
1.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
N Engl J Med;
389(2): 137-147, 2023 Jul 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37272535
2.
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
N Engl J Med;
389(21): 1935-1948, 2023 Nov 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37937763
3.
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
N Engl J Med;
382(1): 41-50, 2020 01 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31751012
4.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
N Engl J Med;
383(18): 1711-1723, 2020 10 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32955177
5.
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
N Engl J Med;
378(2): 113-125, 2018 01 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29151359
6.
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
Future Oncol;
17(35): 4827-4835, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34723634
7.
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
J Mol Diagn;
26(1): 73-84, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37981090
8.
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Target Oncol;
19(2): 131-134, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38466534
9.
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
Nat Commun;
14(1): 1070, 2023 02 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36849494
10.
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Anticancer Drugs;
20(10): 856-66, 2009 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19657272
11.
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res;
25(7): 2058-2063, 2019 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30659024
12.
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res;
25(22): 6644-6652, 2019 11 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31439584
13.
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.
Clin Lung Cancer;
19(4): e533-e536, 2018 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29789220
14.
Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
Nat Commun;
14(1): 3179, 2023 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37263992
15.
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol;
: JCO2018783118, 2018 Aug 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30153097
16.
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol;
36(9): 841-849, 2018 03 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28841389
17.
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Lung Cancer;
104: 119-125, 2017 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28212993
18.
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
J Clin Oncol;
35(36): 4027-4034, 2017 Dec 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28968167
19.
Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.
Oncotarget;
7(35): 57301-57309, 2016 Aug 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27359058
20.
Response to 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis'(Paz-Ares et al., J Cell Mol Med. 2010; 14: 51-69).
J Cell Mol Med;
14(11): 2693-4, 2010 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21029366